High-Throughput Cell Based Assay for the Identification of Drugs Targeting the NF-kB Signaling Pathway
National Jewish Health
Researchers at National Jewish Health have developed a microscopy-based visual assay to measure the antigen-receptor activation of an intermediate molecule located upstream of NF-kB
Identification of compounds as potential agents against inflammatory diseases, immune diseases and cancer
Advantages of Invention
The assay targets Bcl10, a specific intermediate protein of the NF- kB pathway, and it is compatible with epifluorescence/confocal microscopy
State of Development
Using cell lines developed in-house, National Jewish Health scientists have demonstrated that T cell receptor activation of NF-kB involves the dynamic relocalization of the signaling intermediate Bcl10. This protein movement can be visualized by confocal or epifluore scence microscopy using a fluorescent marker (such as GFP) or antibodies.
Issued U.S. Patent #7,169,570
Proc Natl Acad Sci 2004 Jan 27;101(4):1004-9.
Brian Schaefer, PhD, Philippa Marrack, PhD and John Kappler, PhD
This technology is available for licensing.